Cargando…
Defining the critical hurdles in cancer immunotherapy
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move i...
Ejemplares similares
-
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
por: Parmiani, Giorgio, et al.
Publicado: (2015) -
Response definition criteria for ELISPOT assays revisited
por: Moodie, Z., et al.
Publicado: (2010) -
Immunological Monitoring to Rationally Guide AAV Gene Therapy
por: Britten, Cedrik Michael, et al.
Publicado: (2013) -
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn’s hypothesis in the human melanoma system
por: Parmiani, Giorgio, et al.
Publicado: (2012) -
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols
por: Filbert, Helene, et al.
Publicado: (2012)